Compared to either agent alone, the combination of interferon alpha and sorafenib has been found to work better for patients with renal cell carcinoma –the common form of kidney cancer.
Such were the findings of a pilot study led by Duke University Comprehensive Cancer Center researchers.
According to Jared Gollob, M.D., an oncologist at Duke and lead investigator on the study:
“We found that by combining a drug that enlists the immune system’s help in combating cancer with one that cuts off a tumor’s blood supply, we could substantially increase patients’ response rates to treatment.
Most tumors that respond to either therapy alone begin …read more

A combination of TRAIL (a tumor necrosis factor) and sorafenib (an inhibitor currently used to treat renal cancer) has been found to reduce the size of tumors in mice with colon carcinomas with few side effects – thereby demonstrating the potential effectiveness of the combined treatment on human colon cancers.
Such were the new combination therapy identified by the University of Pennsylvania School of Medicine researchers.
According to Wafik S. El-Deiry, MD, PhD, professor of Medicine, Genetics, and Pharmacology:
“Cancer cells will do whatever it takes to survive in harsh environments. Our findings are exciting because TRAIL in combination with sorafenib appears to …read more

Presented Monday at the annual meeting of the American Society of Clinical Oncology, the cure for liver cancer in Sorafenib.
Phase III clinical trial data of this miracle pill revealed that chances of survival from final stage liver cancer is increased by 44% or about three months life extension.
Final stage liver cancer is deadly and currently patients suffering this condition have no treatment option.
Sorafenib is a pill that directly targets malignant cancer cells and cuts off the blood supply feeding the tumour and has been found in a large scale multinational trial, conducted by researchers from the Mount Sinai School of …read more